Skip to Content
MilliporeSigma
  • Binding and displacement of basic, acidic and neutral drugs in normal and orosomucoid-deficient plasma.

Binding and displacement of basic, acidic and neutral drugs in normal and orosomucoid-deficient plasma.

Clinical pharmacokinetics (1981-09-01)
E Pike, B Skuterud, P Kierulf, D Fremstad, S M Abdel Sayed, P K Lunde
ABSTRACT

The binding of the basic drugs quinidine, propranolol and amitriptyline, the neutral drug digitoxin and the acidic drug phenytoin to heparinised normal plasma, to orosomucoid (alpha 1-acid glycoprotein)-deficient plasma and to purified orosomucoid and albumin was studied in both the presence and absence of tris (2-butoxyethyl)-phosphate (TBEP) and de-(2-ethylhexyl)-phthalate (DEHP). The addition of TBEP and DEHP to heparinised plasma in concentrations up to 2.5 mmol/L markedly increased the unbound fractions of quinidine and propranolol, but the increase was less for amitiriptyline, TBEP being the most potent displacer. In orosomucoid-deficient plasma, which was prepared by immunoprecipitation, the free fraction of quinidine was similar to that of normal plasma in which maximal displacement with TBEP was obtained. The addition of the displacers to orosomucoid-deficient plasma caused no further reduction in the binding, nor was the plasma binding of digitoxin and phenytoin significantly affected. When combining purified albumin and orosomucoid in concentrations found in normal plasma, quinidine binding approached that of heparinised normal plasma. This study confirms the dominant role of orosomucoid in the variable plasma binding of basic drugs, and underlines the value of using immunologically prepared orosomucoid-deficient plasma and TBEP or DEHP as model displacers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tris(2-butoxyethyl) phosphate, 94%